VYNE Therapeutics (VYNE) Q3 2025 earnings summary

Executive summary

• Strategic review initiated in August 2025 to explore partnerships, licensing, M&A, and other alternatives to maximize shareholder value, with LifeSci Capital engaged as financial advisor.

• Cost reductions implemented, extending cash runway into the first half of 2027.

• Focused on developing therapies for inflammatory and immune-mediated conditions, with a pipeline centered on BET inhibitors licensed from Tay Therapeutics.

• VYN202, an oral BD2-selective BET inhibitor, is the lead program; a Phase 1b trial in psoriasis was partially held by the FDA due to preclinical toxicity, but promising early data led to a shift in development focus.

• Repibresib gel (VYN201) Phase 2b trial in vitiligo did not meet primary or key secondary endpoints, resulting in trial termination and a search for external partners.

Financial highlights

• Net loss for the nine months ended September 30, 2025 was $21.6 million, a 22% improvement from $27.8 million in the prior year period; Q3 2025 net loss was $7.3 million, improved from $12.2 million in Q3 2024.

• Revenues were $0.4 million for the nine months, consisting solely of royalty income from LEO Pharma, up 5.5% year-over-year; Q3 2025 revenues were $0.2 million.

• Research and development expenses decreased 23.5% year-over-year to $16.3 million for the nine months and 48.7% to $5.3 million for Q3 2025.

• General and administrative expenses fell 13.1% to $8.7 million for the nine months and 8.7% to $2.7 million for Q3 2025.

• Cash, cash equivalents, and marketable securities totaled $32.7 million as of September 30, 2025, with no outstanding debt.

Outlook and guidance

• Existing cash and marketable securities are expected to fund operations for at least 12 months from the reporting date, with cost reductions and strategic review expected to extend the cash runway into the first half of 2027.

• Additional capital will be required for further development of VYN202 and any future product candidates.

• No timetable set for completion of the strategic review; updates will be provided upon material developments.